Abstracts from the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012
Year: 2012
Type: conference-abstract
Abstract: According to recent long-term studies is schizophrenia a chronic disorder with a high risk of poor outcome in terms of symptoms and social functioning and possibly also progressive brain alterations.The relapse rate is high and each relapse can induce further aggravations, both in psychosocial as well as in neurobiological terms.Thus acute and long-term treatment with the highest degree of effectiveness should be provided to the patients in acute and long-term treatment.It is of special interest that some schizophrenia susceptibility genes and chromosomal abnormalities, particularly examined for early onset populations, are associated with premorbid neurodevelopmental abnormalities.Recent MRI imaging studies on patients at risk for schizophrenia showed a specific pattern of brain alterations which is predictive for the development of a full-blown psychosis.In addition to neurodevelopmental disorder, a neuroprogressive brain disorder is increasingly being hypothesized to explain a further decline especially in the poor outcome subgroup of schizophrenic patients.Results from genetic research, especially recently from the genomewide association studies hint at disturbances of neurodevelopment/ neuroplasticity as well as immunological and glutamatergic processes as part of the complex aetiopathogenesis.The relevance of immunological processes is especially supported by results indicating immunological parameter alterations in patients suffering from schizophrenia and especially by the positive outcome of double-blind, randomised add-on studies using the COX-2 inhibitor Celecoxib as add-on to neuroleptic treatment (risperidone, amisulpride).Support for the glutamatergic hypothesis comes primarily from animal models and recently also from the positive outcome of double-blind, randomised trials on new dopaminergic compounds.This glutamatergic approach in the drug treatment seems to be a very promising one, although it currently seems that these compounds are more effective in the treatment of negative symptoms/cognitive symptoms and not so much in positive symptoms.
Authors: Landau, A.M., Wegener, G., Olsen Alstrup, A.K., Jakobsen, S., Audrain, H., Moeller, A., Simonsen, M., Gjedde, A., Videbech, P., Doudet, D.
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,693
Funders: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Stanley Medical Research Institute, Geelong Region Medical Research Foundation, National Alliance for Research on Schizophrenia and Depression, Les Laboratories Pierre Fabre, BrainsWay, European Commission, China Scholarship Council, Servier, H. Lundbeck A/S, National Institutes of Health, Agency for Healthcare Research and Quality, National Health and Medical Research Council
OpenAlex ID: W4293858997